Persistent lineage plasticity driving lung cancer development and progression

Fanchen Meng, J. Li, Zhijun Xia, Qinglin Wang, Qinhong Sun, Siwei Wang, Lin Xu, Rong YinClinical 2025 · DOI

TL;DR

Lung cancer isn't a static disease; it's a dynamic process driven by "lineage plasticity," where cancer cells can change their identity. This review highlights how this cellular flexibility, from the earliest stages of tumor formation through to treatment resistance and metastasis, is a fundamental aspect of lung cancer's complexity and a key target for future therapies.

What Problem Does This Paper Address?

Lung cancer is notoriously heterogeneous, meaning tumors can vary significantly in their cellular makeup and behavior, even within the same patient. This heterogeneity makes it incredibly challenging to treat effectively. While we know that different subtypes of lung cancer exist (adenocarcinoma, squamous cell carcinoma, small cell lung cancer), it's become increasingly clear that these aren't fixed categories. Tumors can actually shift between these subtypes, a phenomenon called "lineage plasticity." This review aims to consolidate our understanding of how this cellular identity change occurs, how it's driven by genetic and epigenetic factors, and how it contributes to tumor progression, immune evasion, and therapy resistance. Understanding this plasticity is crucial for developing more effective and personalized treatment strategies.

Methods

This paper is a review, so it doesn't present new experimental methods. Instead, it synthesizes findings from a vast body of research. The authors draw upon:

  • Genomic and Epigenomic Studies: Analyzing DNA mutations, methylation patterns, and histone modifications to understand the molecular underpinnings of lineage changes.
  • Lineage Tracing: Techniques that track the developmental history and fate of individual cells over time, both in normal development and in cancer.
  • Single-Cell RNA Sequencing (scRNA-seq): A powerful tool to capture the gene expression profiles of individual cells, revealing cellular heterogeneity and identifying distinct cell states within tumors.
  • In Vivo Models: Studies using genetically engineered mouse models (GEMMs) and patient-derived xenografts (PDXs) to investigate tumor development and response to therapy.
  • Bioinformatics and Computational Tools: Analyzing large datasets to model regulatory networks and predict cell fate decisions.

Datasets

Not discussed in the paper.

Key Insights and Ideas

  • Lineage Plasticity is Not Just for Advanced Cancers: This isn't a phenomenon that only kicks in when a tumor is established or resistant to treatment. It's present from the very beginning, influencing tumor initiation and early progression.
  • Normal Development Hijacked: Cancer cells exploit the same cellular plasticity mechanisms that are essential for normal lung development and repair, but in a dysregulated manner.
  • Genetics and Epigenetics are a Dynamic Duo: Specific gene mutations (like EGFR, KRAS, TP53) can predispose cells to certain lineage fates, but it's the interplay with epigenetic modifications (DNA methylation, histone changes) that truly unlocks and drives lineage transitions.
  • The Microenvironment is a Key Player: Factors like hypoxia, immune cells, and the extracellular matrix aren't just passive bystanders; they actively influence cancer cell plasticity, pushing them towards more aggressive or treatment-resistant states.
  • Hybrid EMT States are Highly Malignant: Cells that exist in a "hybrid EMT state," expressing both epithelial and mesenchymal markers, show the highest potential for malignancy and metastasis.
  • Drug Tolerance as a "Plasticity" State: Cancer cells can enter a reversible "drug-tolerant persister" state to evade therapy, and then redifferentiate once treatment is paused, leading to relapse.

Key Results

This review synthesizes a wealth of findings rather than presenting single quantitative results. However, the overarching finding is that lineage plasticity is a pervasive and critical driver of lung cancer across all stages, from initiation to metastasis and treatment resistance. The paper details how specific genetic alterations (e.g., EGFR mutations, KRAS mutations, TP53 loss) are linked to particular lineage shifts and how epigenetic regulators (e.g., EZH2, LSD1, DNMTs) orchestrate these changes. It also highlights the significant impact of the tumor microenvironment, with factors like hypoxia and cytokines from macrophages and cancer-associated fibroblasts promoting EMT and plasticity.

Limitations and Future Work

The authors acknowledge several limitations and propose future directions:

  • Interspecies Differences: Mouse models, while valuable, have significant differences in lung structure, immune systems, and cancer development compared to humans, limiting direct clinical translation.
  • Sample Limitations: Current liquid biopsy techniques (ctDNA, CTCs) have limitations in sensitivity and specificity, and cannot fully capture the spatial heterogeneity of solid tumors.
  • Understanding Epigenetic Dynamics: There's a lack of longitudinal tracking of epigenetic changes during disease progression, hindering a complete understanding of their dynamic roles.
  • Mechanistic Gaps: The precise regulatory networks and induction mechanisms behind lineage plasticity, and how microenvironmental factors interact with genetic/epigenetic mutations, are still not fully understood.
  • Clinical Translation Challenges: Accurately predicting histological transformation and resistance evolution is difficult, and real-time dynamic monitoring of tumor lineage status is lacking.

Future research should focus on:

  • Developing Better Models: Establishing more human-relevant organoid and humanized models.
  • Improving Liquid Biopsy: Enhancing sensitivity and specificity, and integrating epigenetic information.
  • Longitudinal Studies: Collecting multi-center, multi-time-point clinical samples for comprehensive database construction.
  • Targeted Therapies: Developing combination strategies that target plasticity mechanisms, such as epigenetic inhibitors combined with existing therapies, or targeting specific markers of lineage transformation.

Summary updated

Abstract

Lineage plasticity runs through the entire process of lung cancer progression and drug resistance, and drives early tumorigenesis via lineage imbalance. Certain driver mutations have lineage-restricted tumorigenic potential, requiring lineage reprogramming for tumor initiation. Lineage transitions in lung cancer require specific genomic and epigenetic alterations. Lineage plasticity insights provide a mechanistic framework linking lung cancer origin, evolution, and therapeutic vulnerabilities.
BibTeX
@inproceedings{meng2025persistent,
  author = {Fanchen Meng and J. Li and Zhijun Xia and Qinglin Wang and Qinhong Sun and Siwei Wang and Lin Xu and Rong Yin},
  title = {{Persistent lineage plasticity driving lung cancer development and progression}},
  booktitle = {Clinical},
  year = {2025},
  doi = {10.1002/ctm2.70458},
}
Figure